See the latest IASLC meeting news, including an extended deadline for ACLC abstract submissions and COVID-19 guideline updates for those traveling to WCLC. Read more
Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates
Pan-Chyr Yang, MD, PhD+more
Researchers say increased screening of at-risk populations, including those who have never smoked, may improve survival more than any other strategy. Read more
Comparable Efficacy, Disruptive Price for an Alternative EGFR TKI?
H. Jack West, MD+more
Aumolertinib may ultimately prove to be an alternative to osimertinib, but it faces challenges before it can win us fda approval. Read more
Lung Cancer Risk Prediction Model Demonstrates Readiness for Clinical Application
Andrea Borondy Kitts, MS, MPHEvidence demonstrates superior performance of the PLCOm2012 model for identifying individuals for lung cancer screening. Read more
Using Comparative Effectiveness Data Based on Non-Randomized Study Designs to Support Regulatory, Reimbursement Decision-Making
Sreeram Ramagopalan, PhDStudy provides evidence to support the potential role of real-world data in consideration of technologies where only single-arm trial data exists. Read more
In Measuring Outcomes, a Longer-Term View May be Needed
Mark Hennon, MD+more
When publicly reported patient outcomes emerge, the data available to patients should paint the most complete picture possible. Read more
Abstract submission deadlines are approaching for the Asia Conference on Lung Cancer and the North America Conference on Lung Cancer. Read more
Alternative Dosing Strategies for Immune Checkpoint Inhibitors
Michiel Zietse, MSc+more
Combining fixed- and weight-based dosing approaches may reduce costs without compromising efficacy. Read more
US FDA’s Review of Single-Country ‘Me Too’ Drugs: A Clinical Trialist Perspective
Matthew Z. Guo, BA+more
With no direct comparison to the standard of care and limited resources to review applications, researchers say they support the agency’s decision not to approve sintilimab. Read more
Panel Explores Emerging Treatments and Sequencing Strategies for Patients with Advanced NSCLCs Driven by Rare Oncogenes
Beth Fand IncollingoDuring the 2022 European Lung Cancer Congress, experts reviewed evidence on drugs targeting MET exon 14 skipping mutations and RET, HER2, and BRAF alterations. Read more